IRIDEX (IRIDEX) Change In Receivables

: $0.36 Mil (TTM As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

IRIDEX's change in receivables for the quarter that ended in Dec. 2023 was $-1.54 Mil. It means IRIDEX's Accounts Receivable increased by $1.54 Mil from Sep. 2023 to Dec. 2023 .

IRIDEX's change in receivables for the fiscal year that ended in Dec. 2023 was $0.36 Mil. It means IRIDEX's Accounts Receivable declined by $0.36 Mil from Dec. 2022 to Dec. 2023 .

IRIDEX's Accounts Receivable for the quarter that ended in Dec. 2023 was $6.73 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. IRIDEX's Days Sales Outstanding for the three months ended in Dec. 2023 was 49.27.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. IRIDEX's liquidation value for the three months ended in Dec. 2023 was $-7.88 Mil.

IRIDEX Change In Receivables Historical Data

The historical data trend for IRIDEX's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IRIDEX Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-0.27

1.86

-2.47

-0.24

0.36

IRIDEX Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables																-0.02	-0.74	1.96	0.68	-1.54

IRIDEX Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.36 Mil.

IRIDEX (NAS:IRIX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

IRIDEX's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	6.727	/	12.458	*	91
=	49.27

2. In Ben Graham's calculation of liquidation value, IRIDEX's accounts receivable are only considered to be worth 75% of book value:

IRIDEX's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	7.034	-	24.914	+	0.75 * 6.727	+	0.5 * 9.906
=	-7.88

IRIDEX Change In Receivables Related Terms

Thank you for viewing the detailed overview of IRIDEX's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

IRIDEX (IRIDEX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IRIDEX Corp (NAS:IRIX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

1212 Terra Bella Avenue, Mountain View, CA, USA, 94043

Website

https://www.iridex.com

IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.

Executives

Nandini Devi	director	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Beverly A Huss	director	C/O ACCURAY INCORPORATED, 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Robert Earle Grove	director	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Topcon Corp	10 percent owner	75-1, HASUNUMA-CHO, ITABASHI-KU, TOKYO M0 174-8580
Topcon America Corp	10 percent owner	111 BAUER DRIVE, OAKLAND NJ 07426
Fuad Ahmad	officer: Interim CFO	461 SOUTH MILPITAS BLVD., MILPITAS CA 95035
Doris Engibous	director	C/O NATUS MEDICAL INCORPORATED, 1501 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Scott Shuda	director	402 RAILROAD AVENUE, SUITE 201, DANVILLE CA 94526
Patrick Mercer	officer: COO	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Maria Sainz	director	C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Ruediger Naumann-etienne	director
Robert A Gunst	director
David Bruce	director, officer: President and CEO	1178 GLEN ROAD, LAFAYETTE CA 94549
Ken Ludlum	director
Romeo R Dizon	other: Vice President and Controller	1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043